Overall and progression free survival, treated metastasis control for all 361 oligometastatic patients treated with ablative radiotherapy.

<p>Median survival was 47.1 months and 3-year survival was 56% (A). Median progression-free survival was 10.1 months and 3-year progression-free survival was 24% (B). Median treated metastasis control was not reached and 3-year TMC was 72% (C).</p

Univariate and multivariate analysis of per patient treated metastasis control (TMC).

<p>Univariate and multivariate analysis of per patient treated metastasis control (TMC).</p

Univariate and multivariate analysis of overall survival (OS).

<p>Univariate and multivariate analysis of overall survival (OS).</p

Overall and progression free survival, treated metastasis control by minimum biologically effective dose (BED).

<p>BED ≥75 Gy was associated with greater overall survival (p < 0.01) (A) and treated metastasis control (p < 0.01) (C), with trend for progression free survival (p = 0.06) (B).</p

Univariate and multivariate analysis of progression-free survival (PFS).

<p>Univariate and multivariate analysis of progression-free survival (PFS).</p

Recursive partitioning models for overall survival and progression-free survival.

<p>For overall survival, recursive partitioning allowed stratification of patients into five prognostic classes (A). Overall survival was well-stratified based on RPA class (B); log-rank p < 0.01. For progression-free survival, recursive partitioning allowed stratification of patients into two prognostic classes (C). Progression-free survival was well-stratified based on RPA class (D); log-rank p < 0.01.</p

Baseline demographics and clinical characteristics.

<p>Baseline demographics and clinical characteristics.</p